top of page
About
Team
Management
Board Of Directors
Scientific Advisory Board
Scientific and Regulatory Advisors
Clinical
News
Contact
Targeted Solutions for Weight Management and Metabolic Health
Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week
October 17, 2024
Read more...
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
April 23, 2024
Read more
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002
August 17, 2023
Read more
Response Pharmaceuticals Closes Series A Financing
November 21, 2022
Read more
About
Team
Management
Board Of Directors
Scientific Advisory Board
Scientific and Regulatory Advisors
Clinical
News
Contact
bottom of page
